Oxford Immunotec Reports Third Quarter 2016 Financial Results
(Thomson Reuters ONE) -
* Third quarter revenue of $26.1 million, an increase of 46% compared to prior
year period
* Tuberculosis revenue of $22.0 million, an increase of 23% compared to prior
year period
* Tick-borne disease and other revenue of $4.1 million
* Completed acquisitions of Imugen and Immunetics expanding offerings in the
tick-borne disease testing market
* Raising revenue guidance for the full year from $82.5-$84.5 million to
$85.0-$85.8 million
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 01, 2016 (GLOBE NEWSWIRE) --
Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics
company focused on developing and commercializing proprietary tests for the
management of underserved immune-regulated conditions, today announced third
quarter 2016 financial results.
"We are very pleased with our financial and operating results during the third
quarter," said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford
Immunotec. "Sales performance exceeded our expectations in our core tuberculosis
(TB) business with solid organic growth coming from the United States and Asia.
We also saw better than expected results in our tick-borne disease business
which has recently been strengthened through our acquisitions of Imugen and
Immunetics."
By revenue type, total revenues were, in millions:
Three Months Ended September 30,
2016 2015 Percent
Change
Product $ 9.7 $ 8.3 17 %
Service 16.4 9.6 70 %
Total Revenue $ 26.1 $ 17.9 46 %
By indication, total revenues were, in millions:
Three Months Ended September 30,
2016 2015 Percent
Change
Tuberculosis $ 22.0 $ 17.9 23 %
Tick-Borne Disease and Other 4.1 - N/M
Total Revenue $ 26.1 $ 17.9 46 %
By geography, total revenues were, in millions:
Three Months Ended September 30,
Percent Change
2016 2015 As Constant
Reported Currency ((1))
United States $ 16.2 $ 9.3 74 % 74 %
Europe & ROW 1.7 1.6 6 % 15 %
Asia 8.2 7.0 17 % 7 %
Total Revenue $ 26.1 $ 17.9 46 % 41 %
((1) )Changes in revenue include the impact of changes in foreign currency
exchange rates. We use the non-GAAP financial measure "constant currency basis"
in our filings to show changes in our revenue without giving effect to period-
to-period currency fluctuations. We consider the use of a period over period
revenue comparison on a constant currency basis to be helpful to investors, as
it provides a revenue growth measure free of positive or negative volatility due
to currency fluctuations.
Third Quarter 2016 Financial Results
Revenue for the third quarter of 2016 was $26.1 million, representing 46% growth
over the third quarter 2015 revenue of $17.9 million. On a constant currency
basis, revenue growth was 41% versus the prior year period. Revenue for the
third quarter included $4.1 million from Imugen, which the Company acquired on
July 1, 2016. Excluding the impact of Imugen, revenue for the third quarter
increased 23% over the prior year period.
2016 third quarter product revenue was $9.7 million, representing a 17% increase
from product revenue of $8.3 million in the third quarter of 2015. The increase
in product revenue was primarily attributable to growth in Asia. Service revenue
for the third quarter of 2016 was $16.4 million, up 70% from 2015 third quarter
revenue of $9.6 million. The increase in service revenue was primarily driven by
TB volume increases in the United States as well as the acquisition of Imugen.
United States revenue was $16.2 million in the third quarter of 2016,
representing 74% growth over revenue of $9.3 million in the prior year period.
The increase was primarily due to increased service revenue in the United States
as a result of the Imugen acquisition, as well as organic growth in our core TB
business. Excluding the impact of Imugen, United States revenue grew 29% over
the prior year period, driven primarily by increased volume in the institutional
and physician office segments.
Europe & ROW revenue was $1.7 million in the third quarter of 2016, representing
a 6% increase compared to the third quarter of 2015. On a constant currency
basis, Europe & ROW increased 15% versus the third quarter of 2015.
Asia revenue was $8.2 million in the third quarter of 2016, representing 17%
growth over 2015 third quarter revenue of $7.0 million. On a constant currency
basis, Asia grew 7% versus the third quarter of 2015. The increase was driven by
continued growth in Japan and China.
Gross profit for the third quarter of 2016 was $14.6 million, an increase
of $4.7 million over gross profit of $9.9 million in the same period of 2015.
Gross margin was 55.9%, an increase of 90 basis points from the gross margin of
55.0% in the third quarter of 2015. The increase in gross margin was driven by
favorable revenue mix and exchange rate movements.
Operating expenses were $18.9 million in the third quarter of 2016, an increase
of $4.2 million compared to $14.7 million in the same period last year. The
increase in operating expenses was largely due to the inclusion of $1.5 million
in operating expenses from Imugen, as well as increased headcount, acquisition
expenses and legal expenses.
EBITDA for the third quarter was $(3.0) million compared to $(3.8) million in
the third quarter of 2015. Adjusted EBITDA was $(2.2) million for the third
quarter compared to $(2.0) million in the same period in 2015. Both EBITDA and
Adjusted EBITDA are non-GAAP measures.
Net loss for the third quarter of 2016 was $4.0 million, or $0.18 per share,
compared to $4.5 million, or $0.20 per share, in the third quarter of 2015. Net
loss per share was based on 22,365,349 and 22,259,840 weighted average ordinary
shares outstanding for the third quarters of 2016 and 2015, respectively.
Cash and cash equivalents were $37.3 million as of September 30, 2016, compared
to $64.0 million as of June 30, 2016. Cash usage during the quarter was in line
with expectations.
Imugen Acquisition
On July 1, 2016, the Company completed the acquisition of substantially all of
the assets of Imugen, a Massachusetts-based clinical laboratory focused on
developing and performing specialized testing for tick-borne diseases, for $22.2
million in an all cash transaction.
Immunetics Acquisition
On October 12, 2016, the Company completed the acquisition of Immunetics, Inc.,
a Massachusetts-based diagnostics company focused on developing specialized
tests for infectious diseases, such as Lyme disease, for $6 million in cash and
up to an additional $6 million in cash payable on the achievement of certain
revenue thresholds and pipeline related milestones over the next three years.
Debt Financing
On October 4, 2016, the Company entered into an agreement with MidCap Financial
that provided the Company with $40 million in debt financing, comprised of both
a term loan and a revolving line of credit.
The agreement provides the Company with a term loan of $30 million which matures
five years from closing. The term loan accrues interest at a rate of LIBOR plus
7.60% with interest-only payments for the first 24 months, with the ability to
extend to 48 months subject to certain conditions, before the loan begins to
amortize. The agreement also provides the Company with a revolving line of
credit of up to $10 million upon closing. The revolving line of credit matures
five years from closing and accrues interest at LIBOR plus 4.45%. Based on
certain conditions, both the term loan and the revolving line of credit may be
increased by an additional $10 million to support the Company's future growth.
Business Outlook
We expect to report full year 2016 revenue of between $85.0 and $85.8 million,
representing 35%-37% year-over-year growth. This compares to prior guidance of
between $82.5 and $84.5 million.
We expect to report revenue of between $22.6 and $23.4 million for the fourth
quarter of 2016.
We expect to have over $50 million in cash at the end of 2016, excluding any
drawdowns on our revolving line of credit and believe that this capital is
sufficient to allow the Company to achieve profitability.
Conference Call
Oxford Immunotec will host a conference call on Tuesday, November
1, 2016 at 8:00 a.m. Eastern Time to discuss its third quarter 2016 financial
results. The call will be concurrently webcast. To listen to the conference call
on your telephone, please dial (855) 363-5047 for United States callers and +1
(484) 365-2897 for international callers and reference confirmation code
91830521 approximately ten minutes prior to start time. To access the live audio
webcast or subsequent archived recording, visit the Investor Relations section
of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be
available on the Company's website for approximately 60 days.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused
on developing and commercializing proprietary tests for the management of
underserved immune-regulated conditions. The Company's first product is the
TSPOT(®).TB test, which is used to test for tuberculosis infection. The
T-SPOT.TB test has been approved for sale in over 50 countries, including the
United States, where it has received pre-market approval from the Food and Drug
Administration, Europe, where it has obtained a CE mark, as well as Japan and
China. The company's second product line is a range of assays for tick-borne
diseases, such as Lyme disease, obtained through the acquisitions of Imugen and
Immunetics. The T-SPOT.CMV test and the T-SPOT.PRT test are part of the
Company's third product line focused on the transplantation market. In addition
to these three product lines, the Company has additional active development
programs in other immune-regulated conditions. The Company is headquartered near
Oxford, U.K. and in Marlborough, Mass. Additional information can be found
at www.oxfordimmunotec.com.
T-SPOT, the Imugen logo and the Oxford Immunotec logo are trademarks of Oxford
Immunotec Ltd. Immunetics is a trademark of Immunetics, Inc.
Forward-Looking Statements
This release contains forward-looking statements that involve risks and
uncertainties, including statements about our anticipated plans, objectives,
intentions, the anticipated benefits of the transaction, the effects of the
transaction, including effects on future financial and operating results,
prospects for sales of our products and other statements that are not historical
facts. The forward-looking statements in this release are based on current
expectations, assumptions and data available as of the date of this release and
are subject to known and unknown risks and uncertainties that could cause actual
results to differ materially from those expressed or implied by such statements,
including but not limited to: risks related to disruption of management time
from ongoing business operations due to the integration of Imugen and Immunetics
into the Company; the risk that the Company may fail to realize the benefits
expected from the acquisitions; the risk that the integration of Imugen and
Immunetics into the Company may not progress as anticipated; decisions by
regulatory authorities, hospitals and other health care institutions,
laboratories, physicians, patients and third party payers that could affect the
Company's business and prospects; as well as our ability to expeditiously and
successfully expand our sales and distribution networks. The risks included
above are not exhaustive. Other factors that could adversely affect our business
and prospects are described under the "Risk Factors" section in our filings with
the Securities and Exchange Commission ("SEC"). Our filings are available for
free by visiting the investor section of our website, www.oxfordimmunotec.com,
or the SEC's website, www.sec.gov.
Investors should give careful consideration to these risks and uncertainties.
Forward-looking statements contained herein are based on current expectations
and assumptions and currently available data and are neither predictions nor
guarantees of future events or performance. You should not place undue reliance
on forward-looking statements contained herein, which speak only as of the date
of this release. We do not undertake to update or revise any forward-looking
statements after they are made, whether as a result of new information, future
events, or otherwise, except as required by applicable law.
Oxford Immunotec Global PLC
Condensed consolidated statements of operations
(unaudited)
Three months ended September 30, Nine months ended September 30,
(in thousands,
except share 2016 2015 2016 2015
and per share
data)
Revenue
Product $ 9,713 $ 8,310 $ 27,144 $ 22,045
Service 16,396 9,634 35,229 23,952
Total revenue 26,109 17,944 62,373 45,997
Cost of
revenue
Product 3,616 3,757 10,421 9,712
Service 7,887 4,312 17,853 11,514
Total cost of 11,503 8,069 28,274 21,226
revenue
Gross profit 14,606 9,875 34,099 24,771
Operating
expenses:
Research and 3,592 3,187 10,009 8,392
development
Sales and 8,794 7,381 26,665 22,549
marketing
General and 6,466 4,137 16,200 11,788
administrative
Total
operating 18,852 14,705 52,874 42,729
expenses
Loss from (4,246 ) (4,830 ) (18,775 ) (17,958 )
operations
Other
(expense)
income:
Interest (54 ) (19 ) (88 ) (53 )
expense, net
Foreign
exchange gains 470 476 1,707 (33 )
(losses)
Other
(expense) (106 ) (64 ) (243 ) 50
income
Loss before (3,936 ) (4,437 ) (17,399 ) (17,994 )
income taxes
Income tax 60 46 92 94
expense
Net loss $ (3,996 ) $ (4,483 ) $ (17,491 ) $ (18,088 )
Net loss per
share
attributable
to ordinary $ (0.18 ) $ (0.20 ) $ (0.78 ) $ (0.84 )
shareholders-
basic and
diluted
Weighted-
average shares
used to
compute net
loss 22,365,349 22,259,840 22,333,911 21,619,375
attributable
to ordinary
shareholders-
basic and
diluted
Reconciliation of net loss to Adjusted EBITDA ((1))
(unaudited)
Three months Nine months
ended September 30, ended September 30,
(in 2016 2015 2016 2015
thousands)
Net loss $ (3,996 ) $ (4,483 ) $ (17,491 ) $ (18,088 )
Income tax 60 46 92 94
expense
Interest 54 19 88 53
expense, net
Depreciation
and 862 597 2,067 1,533
amortization
EBITDA (3,020 ) (3,821 ) (15,244 ) (16,408 )
Reconciling
items:
Share-based
compensation 1,368 994 3,827 2,582
expense
Unrealized
exchange (572 ) 422 (1,990 ) (193 )
losses
(gains)
Change in
fair value of
contingent 60 52 172 148
purchase
price
consideration
Intangible
asset - 385 - 385
impairment
charge
Adjusted $ (2,164 ) $ (1,968 ) $ (13,235 ) $ (13,486 )
EBITDA
((1)) EBITDA and Adjusted EBITDA are non-GAAP measures that we calculate as net
loss, adjusted for the impact of earnings or charges resulting from matters that
we consider not to be indicative of our ongoing operations. We believe that
these measures provide useful information to investors in understanding and
evaluating our operating results in the same manner as our management and Board
of Directors. Our presentation of these measures is not made in accordance with
U.S. GAAP, and our computation of these measures may vary from others in the
industry. Our use of these measures has limitations as an analytical tool, and
you should not consider it in isolation or as a substitute for analysis of our
results as reported under U.S. GAAP.
The above table presents a reconciliation of net loss, the most comparable U.S.
GAAP measure, to EBITDA and Adjusted EBITDA for each of the periods indicated.
Oxford Immunotec Global PLC
Condensed consolidated balance sheets
(unaudited)
September 30,
December 31,
(in thousands, except share and per 2016 2015
share data)
Assets
Current assets:
Cash and cash equivalents $ 37,324 $ 83,715
Accounts receivable, net 15,139 7,058
Inventory, net 7,313 7,099
Prepaid expenses and other assets 2,212 3,592
Total current assets 61,988 101,464
Restricted cash, non-current 200 80
Property and equipment, net 7,185 6,284
In-process research and development 11,031 1,782
Goodwill 2,691 45
Other intangible assets, net 9,648 179
Other assets 144 18
Total assets $ 92,887 $ 109,852
Liabilities and shareholders' equity
Current liabilities:
Accounts payable $ 2,254 $ 3,799
Accrued liabilities 11,314 9,949
Deferred income 53 1,654
Current portion of loans payable 82 79
Total current liabilities 13,703 15,481
Long-term portion of loans payable 323 386
Contingent purchase price consideration 1,502 1,293
Total liabilities 15,528 17,160
Shareholders' equity:
Ordinary shares, £0.006705 nominal
value; 36,183,293 shares authorized at
September 30, 2016 and December
31, 2015, and 22,581,222 and 22,549,488 243 243
shares issued and outstanding at
September 30, 2016 and December
31, 2015, respectively
Additional paid-in capital 247,875 244,033
Accumulated deficit. (163,798 ) (146,307 )
Accumulated other comprehensive loss (6,961 ) (5,277 )
Total shareholders' equity 77,359 92,692
Total liabilities and shareholders' $ 92,887 $ 109,852
equity.
CONTACTS:
For Media Inquiries:
Caroline Crawley
Oxford Immunotec
Tel: +44 1235 442796
ccrawley(at)oxfordimmunotec.com
For Investor Inquiries:
Rick Altieri
Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953
raltieri(at)oxfordimmunotec.com
Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0501
oxfordimmunotec(at)westwicke.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Sibanye takes ownership of the Rustenburg Platinum Mines and implements management changes
Datum: 01.11.2016 - 12:00 Uhr
Sprache: Deutsch
News-ID 504143
Anzahl Zeichen: 24019
contact information:
Town:
Oxfordshire
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 202 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Oxford Immunotec Reports Third Quarter 2016 Financial Results"
steht unter der journalistisch-redaktionellen Verantwortung von
Oxford Immunotec (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
